Actuate Therapeutics Inc (ACTU) has a current Price-to-Book (P/B) ratio of 12.82. Compared to its 3-year average P/B ratio of 139.61, the current P/B ratio is approximately -90.82% higher. Relative to its 5-year average P/B ratio of 139.61, the current P/B ratio is about -90.82% higher. Actuate Therapeutics Inc (ACTU) has a Forward Free Cash Flow (FCF) yield of approximately -14.44%. Compared to its 3-year average FCF yield of -13.66%, the current FCF yield is approximately 5.73% lower. Relative to its 5-year average FCF yield of -13.66%, the current FCF yield is about 5.73% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for ACTU competitors is 12.48, providing a benchmark for relative valuation. Actuate Therapeutics Inc Corp (ACTU.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of ACTU increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of ACTU in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is ACTU currently overvalued or undervalued?

What is Actuate Therapeutics Inc (ACTU) fair value?

ACTU's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Actuate Therapeutics Inc (ACTU) is between to according to relative valuation method.

How does ACTU's valuation metrics compare to the industry average?

The average P/S ratio for ACTU's competitors is 12.48, providing a benchmark for relative valuation. Actuate Therapeutics Inc Corp (ACTU) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Actuate Therapeutics Inc (ACTU) as of Mar 03 2026?

As of Mar 03 2026, Actuate Therapeutics Inc (ACTU) has a P/B ratio of 12.82. This indicates that the market values ACTU at 12.82 times its book value.

What is the current FCF Yield for Actuate Therapeutics Inc (ACTU) as of Mar 03 2026?

As of Mar 03 2026, Actuate Therapeutics Inc (ACTU) has a FCF Yield of -14.44%. This means that for every dollar of Actuate Therapeutics Inc's market capitalization, the company generates -14.44 cents in free cash flow.

What is the current Forward P/E ratio for Actuate Therapeutics Inc (ACTU) as of Mar 03 2026?

As of Mar 03 2026, Actuate Therapeutics Inc (ACTU) has a Forward P/E ratio of -6.35. This means the market is willing to pay $-6.35 for every dollar of Actuate Therapeutics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Actuate Therapeutics Inc (ACTU) as of Mar 03 2026?

As of Mar 03 2026, Actuate Therapeutics Inc (ACTU) has a Forward P/S ratio of 0.00. This means the market is valuing ACTU at $0.00 for every dollar of expected revenue over the next 12 months.

ACTU Valuation